Quotes 5-day view Delayed Nyse
10/19/2020
10/20/2020
10/21/2020
10/22/2020
10/23/2020
Date
142.8(c)
143.59(c)
141.31(c)
141.65(c)
142.38(c)
Last
3 158 872
2 188 844
1 983 653
3 057 821
2 410 163
Volume
-2.27% +0.55% -1.59% +0.24% +0.52% Change
Sales 2020
23 794 M - -
Net income 2020
6 198 M - -
Net Debt 2020
11 489 M - -
P/E ratio 2020
21,6x
Yield 2020
2,10%
Sales 2021
25 968 M - -
Net income 2021
7 329 M - -
Net Debt 2021
8 478 M - -
P/E ratio 2021
18,0x
Yield 2021
2,29%
Capitalization
129 B 129 B -
EV / Sales 2020
5,91x
EV / Sales 2021
5,30x
Nbr of Employees
33 625
Free-Float
99,8%
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both...
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
All news about ELI LILLY AND COMPANY
News in other languages on ELI LILLY AND COMPANY
ELI LILLY AND COMPANY - 10/16
The underlying trend is in force again
BUY
Lilly hires external adviser for COVID-19 drug plant problems
Chart ELI LILLY AND COMPANY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ELI LILLY AND COMPANY
Short Term Mid-Term Long Term Trends Bearish Bearish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
19
Average target price
167,11 $
Last Close Price
142,38 $
Spread / Highest target
40,5%
Spread / Average Target
17,4%
Spread / Lowest Target
-15,7%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
